Global Hunter Securities Starts ZIOPHARM Oncology (ZIOP) at Buy; Poised for Progress in 2012
Tweet
Share
E-mailGet Alerts ZIOP Hot Sheet
Price: $0.87 --0%
Rating Summary:
6 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Global Hunter Securities initiates coverage on ZIOPHARM Oncology (NASDAQ: ZIOP) with a Buy. PT $9.00.
Global analyst says, "ZIOPHARM Oncology’s most advanced product candidate is palifosfamide, which is in Phase III evaluation as a front-line treatment for metastatic soft tissue sarcoma (STS) in a clinical trial named PICASSO 3. We believe the interim analysis of PICASSO 3 in 2H12 will be positive, strongly positioning the company to gain accelerated approval of palifosfamide for use in front-line STS in 2014, and full approval upon meeting the OS endpoint in 2015. Palifosfamide has also demonstrated results supporting strong rationale for evaluation in small cell lung cancer. ZIOPHARM is also pursuing development of other novel therapeutics that target unmet medical needs, such as the organic arsenical compound darinaparsin, in peripheral T cell lymphoma, the tubulin inhibitor indibulin, in metastatic breast cancer, and DNA-based synthetic therapies through its collaboration with privately held Intrexon."
For an analyst ratings summary and ratings history on ZIOPHARM Oncology click here. For more ratings news on ZIOPHARM Oncology click here.
Shares of ZIOPHARM Oncology closed at $4.23 yesterday.
Global analyst says, "ZIOPHARM Oncology’s most advanced product candidate is palifosfamide, which is in Phase III evaluation as a front-line treatment for metastatic soft tissue sarcoma (STS) in a clinical trial named PICASSO 3. We believe the interim analysis of PICASSO 3 in 2H12 will be positive, strongly positioning the company to gain accelerated approval of palifosfamide for use in front-line STS in 2014, and full approval upon meeting the OS endpoint in 2015. Palifosfamide has also demonstrated results supporting strong rationale for evaluation in small cell lung cancer. ZIOPHARM is also pursuing development of other novel therapeutics that target unmet medical needs, such as the organic arsenical compound darinaparsin, in peripheral T cell lymphoma, the tubulin inhibitor indibulin, in metastatic breast cancer, and DNA-based synthetic therapies through its collaboration with privately held Intrexon."
For an analyst ratings summary and ratings history on ZIOPHARM Oncology click here. For more ratings news on ZIOPHARM Oncology click here.
Shares of ZIOPHARM Oncology closed at $4.23 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
- Evercore ISI Starts Alvotech SA (ALVO) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
